Accès ouvert
2026
article
OpenAlex
Kelly Meza, Carla Barrientos Risso, Ankit Shah, Carla Romagnoli et autres
Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically with the introduction of targeted agents, particularly Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). This review summarizes contemporary frontline and relapsed/refractory treatment strategies, with an emphasis on molecular risk stratification, combination …
us
(code pays fourni par la source)
2026
article
OpenAlex
Kelly Meza-Capcha, Mitchell Boshkos, Humberto Nieves Jimenez, Carla Romagnoli et autres
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that, in adults, is most commonly secondary to malignancy. Lymphoma-associated HLH (LA-HLH) is typically driven by aggressive non-Hodgkin lymphomas, while Hodgkin lymphoma is reported infrequently. We conducted a retrospective, multicenter analysis of adults diagnosed …
us
(code pays fourni par la source)
Accès ouvert
2026
preprint
OpenAlex
Kelly Meza, Carla Barrientos Risso, Ankit Shah, Carla Romagnoli et autres
Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically with the introduction of targeted agents, particularly Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). This review summarizes contemporary frontline and relapsed/refractory treatment strategies, with an emphasis on molecular risk stratification, combination …
Accès ouvert
2024
article
OpenAlex
Michael; https://orcid.org/0000-0002-1605-7875 Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons et autres
Accès ouvert
2015
article
OpenAlex
John Pagel, Jennifer Brown, Peter Hillmen, Susan O'Brien et autres
Updated efficacy including genetic subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously-treated CLL/SLL
us, au, at, fr, ie, it, es, Afrique du Sud
(code pays fourni par la source)